Very recently, Zhao et al. [40] designed an in vivo experimentto evaluate CRISPR/Cas9 delivered by AAV as a method of targeted genome editingto restore the function of LDLR and improve atherosclerosis in cases with HoFH.They produced a mouse model of atherosclerosis, LdlrE⁢208⁢X, by inserting anonsense mutation. The gene discussed is LDLR; the disease is atherosclerosis.